系统性硬化症相关间质性肺病患者治疗偏好:一项离散选择实验
该研究采用离散选择实验量化231例系统性硬化症相关间质性肺病(SSc-ILD)患者对7种治疗属性的偏好。患者偏好每日两次口服治疗和每6-12个月输注一次,选择主要受胃肠道不良事件或感染风险影响,呼吸症状改善比皮肤紧绷改善更重要。患者愿意在不同属性间进行权衡,为临床共享决策提供依据。
要点
- 患者偏好每日两次口服治疗和每6-12个月输注一次。
- 患者选择主要受胃肠道不良事件风险或感染风险影响。
- 呼吸症状改善比皮肤紧绷改善更重要。
核心结论
- 这是首项定量引出SSc-ILD患者治疗属性偏好的研究,患者表现出愿意进行权衡,为临床共享决策提供了坚实基础。
研究设计与样本
- 通过混合方法研究和临床医生意见确定7种SSc-ILD治疗属性:给药方式、气短、皮肤紧绷、咳嗽、疲倦、胃肠道不良事件(GI-AEs)风险以及严重和非严重感染风险。
- 231例SSc-ILD患者完成在线离散选择实验(DCE),反复在两种由不同属性严重程度水平描述的替代方案间选择。
- 数据采用多项logit模型分析,计算相对属性重要性和最大可接受风险。
主要发现
- 患者偏好每日两次口服治疗和每6-12个月输注一次。
- 患者选择主要受胃肠道不良事件风险或感染风险影响。
- 呼吸症状改善比皮肤紧绷改善更重要。
- 若减少输注频率,患者接受胃肠道不良事件风险增加21%;若改为口服治疗,接受增加15%;若改善气短,接受增加至多37%;若降低感染风险,接受增加至多36%。
关键数值与推荐
- 若减少输注频率,患者接受的胃肠道不良事件风险增加为+21%。
- 若改为口服治疗,患者接受的胃肠道不良事件风险增加为+15%。
- 若改善气短,患者接受的胃肠道不良事件风险增加为至多+37%。
- 若降低感染风险,患者接受的胃肠道不良事件风险增加为至多+36%。
临床怎么用
- 患者愿意在不同治疗属性间进行权衡,为临床实践中的共享决策提供了坚实基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Treatments for SSc-associated interstitial lung disease (SSc-ILD) differ in attributes, i.e. mode of administration, adverse events (AEs) and efficacy. As physicians and patients may perceive treatments differently, shared decision-making can be essential for optimal treatment provision. We therefore aimed to quantify patient preferences for different treatment attributes. METHODS: Seven SSc-ILD attributes were identified from mixed-methods research and clinician input: mode of administration, shortness of breath, skin tightness, cough, tiredness, risk of gastrointestinal AEs (GI-AEs) and risk of serious and non-serious infections. Patients with SSc-ILD completed an online discrete choice experiment (DCE) in which they were asked to repeatedly choose between two alternatives characterized by varying severity levels of the included attributes. The data were analysed using a multinomial logit model; relative attribute importance and maximum acceptable risk measures were calculated. RESULTS: Overall, 231 patients with SSc-ILD completed the DCE. Patients preferred twice-daily oral treatments and 6-12 monthly infusions. Patients' choices were mostly influenced by the risk of GI-AEs or infections. Improvement was more important in respiratory symptoms than in skin tightness. Concerning trade-offs, patients accepted different levels of increase in GI-AE risk: +21% if it reduced the infusions' frequency; +15% if changing to an oral treatment; up to +37% if it improved breathlessness; and up to +36% if it reduced the risk of infections. CONCLUSIONS: This is the first study to quantitatively elicit patients' preferences for treatment attributes in SSc-ILD. Patients showed willingness to make trade-offs, providing a firm basis for shared decision-making in clinical practice.
引用
- Bruni C, Heidenreich S, Duenas A, et al. Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology (Oxford). 2022. PMID: 35238334. doi:10.1093/rheumatology/keac126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。